OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab

OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab

OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationale Chronic Pouchitis offers a capital-efficient rare-disease path with fast route to market Hidradenitis Suppurativa enables rapid proof-of-concept in a large dermatology market First Phase 2 clinical trial expected to start in H2 2026, subject to financing Ulcerative Colitis …

OSE expands lusvertikimab into new immune-mediated indications - BioTuesdays

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has announced that it has selected chronic pouchitis and hidradenitis suppurativa (HS) as new key indications for lusvertikimab, a potential first-in-class IL-7R antagonist. According to OSE, these indications were selected based on strong, IL-7R-driven biology and are fully aligned with the company’s 2026–2028 strategic plan to expand lusvertikimab into targeted, high value immune-mediated…